Journal Summary - Discover more summaries and articles from M3 India

Dermatology

Choose Topic

Efficacy and safety of pimecrolimus 1% vs sertaconazole 2% in facial seborrheic dermatitis treatment

Clinical and Experimental Dermatology | Jan 28, 2022 Dermatopathology Derm Allergy/Immunology Dermatology Clinical Pharmacology

Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study

Journal of the American Academy of Dermatology | Jan 27, 2022 Clinical Pharmacology Diagnostics/Radiology Derm Allergy/Immunology Dermatology Autoimmune/Bullous Dz Radiology/Diagnostics Allergy/Immunology

Efficacy of ablative fractional carbon dioxide laser combined with autologous platelet‐rich plasma vs ablative fractional carbon dioxide laser and placebo in the treatment of striae gravidarum: A randomized clinical trial

Journal of Cosmetic Dermatology | Jan 27, 2022 Obstetrics Clinical Pharmacology Dermatopathology Dermatology Women`s Health

Risk of all-cause mortality, CVD mortality, and cancer mortality in bullous pemphigoid

JAMA | Jan 06, 2022 General Dermatology Clinical Pharmacology Autoimmune/Bullous Dz

Diagnostic accuracy of clinical examination and ultrasonography for detecting metastasis

JAMA | Jan 06, 2022 Dermatologic Oncology General Dermatology

Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: Final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Clinical Epidemiology | Jan 06, 2022 Dermatologic Oncology General Dermatology Derm Allergy/Immunology Clinical Pharmacology

Trial of spesolimab for generalized pustular psoriasis

New England Journal of Medicine | Jan 05, 2022 Clinical Pharmacology General Dermatology Psoriasis

Improvement of mortality prognostication in patients with epidermal necrolysis: The role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)

JAMA | Jan 05, 2022 Dermatopathology General Dermatology

Identifying Brigham and Women's Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes

Journal of the American Academy of Dermatology | Jan 05, 2022 Dermatologic Oncology General Dermatology

Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: Placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)

British Journal of Dermatology | Jan 05, 2022 Derm Allergy/Immunology Clinical Pharmacology General Dermatology

« Prev 1 2 3 4 5 6 … 309 Next »

Efficacy and safety of pimecrolimus 1% vs sertaconazole 2% in facial seborrheic dermatitis treatment

Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study

Efficacy of ablative fractional carbon dioxide laser combined with autologous platelet‐rich plasma vs ablative fractional carbon dioxide laser and placebo in the treatment of striae gravidarum: A randomized clinical trial

Risk of all-cause mortality, CVD mortality, and cancer mortality in bullous pemphigoid

Diagnostic accuracy of clinical examination and ultrasonography for detecting metastasis

Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: Final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Trial of spesolimab for generalized pustular psoriasis

Improvement of mortality prognostication in patients with epidermal necrolysis: The role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)

Identifying Brigham and Women's Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes

Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: Placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)

Alternative Therapies and Infection Management

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Pulmonary Embolism: MCQs Challenge

Pelvic Floor Disorders: Causes, Diagnosis & Treatment

Top Foods to Combat Winter Illness

Efficacy and safety of pimecrolimus 1% vs sertaconazole 2% in facial seborrheic dermatitis treatment

Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study

Efficacy of ablative fractional carbon dioxide laser combined with autologous platelet‐rich plasma vs ablative fractional carbon dioxide laser and placebo in the treatment of striae gravidarum: A randomized clinical trial

Risk of all-cause mortality, CVD mortality, and cancer mortality in bullous pemphigoid

Diagnostic accuracy of clinical examination and ultrasonography for detecting metastasis

Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: Final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Trial of spesolimab for generalized pustular psoriasis

Improvement of mortality prognostication in patients with epidermal necrolysis: The role of novel inflammatory markers and proposed revision of SCORTEN (Re-SCORTEN)

Identifying Brigham and Women's Hospital stage T2a cutaneous squamous cell carcinomas at risk of poor outcomes

Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: Placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)

Alternative Therapies and Infection Management

'Weekend Warrior' Trend: Health Perks for Busy Physicians

Pulmonary Embolism: MCQs Challenge

Pelvic Floor Disorders: Causes, Diagnosis & Treatment

Top Foods to Combat Winter Illness

Select Specialty

Select Topic